Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2 011.05
3 605.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Dr. Lal PathLabs Ltd
Dr. Lal PathLabs Ltd
Revenue
Dr. Lal PathLabs Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
Revenue
₹23.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Dr Agarwal's Eye Hospital Ltd
BSE:526783
|
Revenue
₹3.4B
|
CAGR 3-Years
30%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
Revenue
₹5.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
Revenue
₹5.5B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Krsnaa Diagnostics Ltd
NSE:KRSNAA
|
Revenue
₹6.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Metropolis Healthcare Ltd
NSE:METROPOLIS
|
Revenue
₹12.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Dr. Lal PathLabs Ltd
Glance View
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,110 full-time employees. The company went IPO on 2015-12-23. The firm is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The firm offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.
See Also
What is Dr. Lal PathLabs Ltd's Revenue?
Revenue
23.5B
INR
Based on the financial report for Sep 30, 2024, Dr. Lal PathLabs Ltd's Revenue amounts to 23.5B INR.
What is Dr. Lal PathLabs Ltd's Revenue growth rate?
Revenue CAGR 5Y
13%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Dr. Lal PathLabs Ltd have been 6% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
